121 related articles for article (PubMed ID: 10362149)
1. Cytotoxicity with Auger electron-emitting radionuclides delivered by antibodies.
Griffiths GL; Govindan SV; Sgouros G; Ong GL; Goldenberg DM; Mattes MJ
Int J Cancer; 1999 Jun; 81(6):985-92. PubMed ID: 10362149
[TBL] [Abstract][Full Text] [Related]
2. A comparison of 4 radionuclides conjugated to antibodies for single-cell kill.
Michel RB; Brechbiel MW; Mattes MJ
J Nucl Med; 2003 Apr; 44(4):632-40. PubMed ID: 12679410
[TBL] [Abstract][Full Text] [Related]
3. Localization of an antibody to CD74 (MHC class II invariant chain) to human B cell lymphoma xenografts in nude mice.
Shih L; Ong GL; Burton J; Mishina D; Goldenberg DM; Mattes MJ
Cancer Immunol Immunother; 2000 Jul; 49(4-5):208-16. PubMed ID: 10941903
[TBL] [Abstract][Full Text] [Related]
4. Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with beta-particle emitters.
Govindan SV; Goldenberg DM; Elsamra SE; Griffiths GL; Ong GL; Brechbiel MW; Burton J; Sgouros G; Mattes MJ
J Nucl Med; 2000 Dec; 41(12):2089-97. PubMed ID: 11138697
[TBL] [Abstract][Full Text] [Related]
5. Single-cell cytotoxicity with radiolabeled antibodies.
Ong GL; Elsamra SE; Goldenberg DM; Mattes MJ
Clin Cancer Res; 2001 Jan; 7(1):192-201. PubMed ID: 11205908
[TBL] [Abstract][Full Text] [Related]
6. In vitro toxicity of A-431 carcinoma cells with antibodies to epidermal growth factor receptor and epithelial glycoprotein-1 conjugated to radionuclides emitting low-energy electrons.
Michel RB; Castillo ME; Andrews PM; Mattes MJ
Clin Cancer Res; 2004 Sep; 10(17):5957-66. PubMed ID: 15355929
[TBL] [Abstract][Full Text] [Related]
7. Therapy of small subcutaneous B-lymphoma xenografts with antibodies conjugated to radionuclides emitting low-energy electrons.
Michel RB; Rosario AV; Andrews PM; Goldenberg DM; Mattes MJ
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):777-86. PubMed ID: 15701868
[TBL] [Abstract][Full Text] [Related]
8. Therapy of disseminated B-cell lymphoma xenografts in severe combined immunodeficient mice with an anti-CD74 antibody conjugated with (111)indium, (67)gallium, or (90)yttrium.
Ochakovskaya R; Osorio L; Goldenberg DM; Mattes MJ
Clin Cancer Res; 2001 Jun; 7(6):1505-10. PubMed ID: 11410483
[TBL] [Abstract][Full Text] [Related]
9. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.
Sharkey RM; Behr TM; Mattes MJ; Stein R; Griffiths GL; Shih LB; Hansen HJ; Blumenthal RD; Dunn RM; Juweid ME; Goldenberg DM
Cancer Immunol Immunother; 1997 May; 44(3):179-88. PubMed ID: 9191878
[TBL] [Abstract][Full Text] [Related]
10. Experimental therapy of disseminated B-Cell lymphoma xenografts with 213Bi-labeled anti-CD74.
Michel RB; Rosario AV; Brechbiel MW; Jackson TJ; Goldenberg DM; Mattes MJ
Nucl Med Biol; 2003 Oct; 30(7):715-23. PubMed ID: 14499329
[TBL] [Abstract][Full Text] [Related]
11. Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas.
Hansen HJ; Ong GL; Diril H; Valdez A; Roche PA; Griffiths GL; Goldenberg DM; Mattes MJ
Biochem J; 1996 Nov; 320 ( Pt 1)(Pt 1):293-300. PubMed ID: 8947500
[TBL] [Abstract][Full Text] [Related]
12. The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibody.
Mattes MJ; Shih LB; Govindan SV; Sharkey RM; Ong GL; Xuan H; Goldenberg DM
Int J Cancer; 1997 May; 71(3):429-35. PubMed ID: 9139880
[TBL] [Abstract][Full Text] [Related]
13. 177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo.
Michel RB; Andrews PM; Rosario AV; Goldenberg DM; Mattes MJ
Nucl Med Biol; 2005 Apr; 32(3):269-78. PubMed ID: 15820762
[TBL] [Abstract][Full Text] [Related]
14. Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines.
Ong GL; Goldenberg DM; Hansen HJ; Mattes MJ
Immunology; 1999 Oct; 98(2):296-302. PubMed ID: 10540230
[TBL] [Abstract][Full Text] [Related]
15. Radionuclide-antibody conjugates for single-cell cytotoxicity.
Mattes MJ
Cancer; 2002 Feb; 94(4 Suppl):1215-23. PubMed ID: 11877748
[TBL] [Abstract][Full Text] [Related]
16. Antibody localization to B-cell lymphoma xenografts in immunodeficient mice: importance of using residualizing radiolabels.
Michel RB; Ochakovskaya R; Mattes MJ
Clin Cancer Res; 2002 Aug; 8(8):2632-9. PubMed ID: 12171895
[TBL] [Abstract][Full Text] [Related]
17. Cellular association and cytotoxicity of anti-CD74-targeted lipid drug-carriers in B lymphoma cells.
Lundberg BB; Griffiths G; Hansen HJ
J Control Release; 2004 Jan; 94(1):155-61. PubMed ID: 14684279
[TBL] [Abstract][Full Text] [Related]
18. Intracellular processing of 99Tcm-antibody conjugates.
Karacay H; Ong GL; Hansen HJ; Griffiths GL; Goldenberg DM; Mattes MJ
Nucl Med Commun; 1998 Oct; 19(10):971-9. PubMed ID: 10234677
[TBL] [Abstract][Full Text] [Related]
19. CD74: a new candidate target for the immunotherapy of B-cell neoplasms.
Stein R; Mattes MJ; Cardillo TM; Hansen HJ; Chang CH; Burton J; Govindan S; Goldenberg DM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5556s-5563s. PubMed ID: 17875789
[TBL] [Abstract][Full Text] [Related]
20. Therapy of human carcinoma xenografts with antibodies to EGFr and HER-2 conjugated to radionuclides emitting low-energy electrons.
Mattes MJ; Goldenberg DM
Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1249-58. PubMed ID: 18265976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
